Identification and characterization of new impurities in rivastigmine

Pharmazie

Volumn 65, Issue 5, 2010, Pages 336-338

  Rao, M Srinivasa ^a   Rao, Sumathi V ^a   Rao, D V N Srinivasa ^a   Bharathi, Ch ^a   Rajput, Pradeep ^a   Sharma, Hemant Kumar ^a  

^a APL Research Centre   (India)

Author keywords

[No Author keywords available]

Indexed keywords

N,N DIETHYL 3 [1 DIMETHYLAMINOETHYL]PHENYLCARBOXAMIDE(DIETHYL RIVASTIGMINE); N,N DIMETHYL 3 [1 DIMETHYLAMINOETHYL]PHENYLCARBOXYLATE(DIMETHYL RIVASTIGMINE); RIVASTIGMINE; UNCLASSIFIED DRUG;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG IMPURITY; DRUG ISOLATION; DRUG RETENTION; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PROTON NUCLEAR MAGNETIC RESONANCE; REVERSED PHASE LIQUID CHROMATOGRAPHY;

CHOLINESTERASE INHIBITORS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CONTAMINATION; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; PHENYLCARBAMATES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 77953068150     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2010.8192     Document Type: Article

References (11)

1. Enz A, Chappuis A, Dattler A (2004) A simple, rapid and sensitive method for simultaneous determination of rivastigmine and its major metabolite NAP 226-90 in rat brain and plasma by reversed-phase liquid chromatography coupled to electrospray ionization mass spectrometry. Biomed Chromatogr 18: 160-166. (Pubitemid 38584833)
2. ICH Guideline Q3A (R), Impurities in New Drug Substances, 7 February 2002.
3. Kavalìrova A, Pospisilova M, Karlicek R (2004) Enantiomeric analysis of rivastigmine in pharmaceuticals by cyclodextrin-modified capillary zone electrophoresis. Anal Chim Acta 525: 43-51. (Pubitemid 39330385)
4. Kenndler E, Lucangioli SE, Tripodi V, Masrian E, Sciocia SL, Carducci CN (2005) Enantioselective separation of rivastigmine by capillary electrophoresis with cyclodextrines. J Chromatogr A 1081: 31-35. (Pubitemid 40799226)
5. Martindale (2002) The Complete Drug Reference. 33.ed., London.
6. Melchiorre C, Bolognesi ML, Bartolini M, Cavalli A, Andrisano V, Rosini M, Minarini A (2004) Design, synthesis and biological evaluation of conformationally restricted rivastigmine analogues. J Med Chem 47: 5945-5952. (Pubitemid 39507336)
7. Pommier F, Frigola R (2003) Quantitative determination of rivastigmine and its major metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. J Chromatogr B 784: 301-313. (Pubitemid 36044013)
8. Srinivasu MK, Mallikarjuna Rao B, Praveen Kumar K, Bhradwaj N, Ravi R, Mohakhud PK, Om Reddy G, Rajender Kumar R (2005b) A stability indicating LC method for rivastigmine hydrogen tartrate. J Pharm Biomed Anal 37: 57-63. (Pubitemid 40138716)
9. Srinivasu MK, Mallikarjuna Rao B, Sundar Reddy BS, Rajeneder Kumer P, Chandrasekher KB, Mohakhud PK (2005a); A validated chiral liquid chromatographic method for the enantiomeric separation of rivastigmine hydrogen tartrate, a cholinesterase inhibitor. J Pharm Biomed Anal 38: 320-325.
10. 14C]SDZ ENA 713, an acetylcholinesterase inhibitor, in minipigs following oral, intravenous and dermal administration. Pharm Res 15: 1614-1620.
11. Wang, Z.Y, Xu, XX, Hu, ZD, Kang, JW (2006) Sensitive method for enantioseparation of rivastigmine with highly sulfated cyclodextrin as chiral selector by capillary electrophoresis. Chin J Chem 24: 1384-1387.